3,5-Bis-(1H-benzoimidazol-2-yl)-1H-indazole | 485838-79-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3,5-Bis-(1H-benzoimidazol-2-yl)-1H-indazole
• 英文别名: 3,5-bis(1H-benzimidazol-2-yl)-1H-indazole
• CAS: 485838-79-7
• 化学式: C₂₁H₁₄N₆
• 分子量: 350.382
• InChiKey: YDXMSRVTGDSWKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1H-indazole-3,5-dicarboxaldehyde 、 邻苯二胺 生成 3,5-Bis-(1H-benzoimidazol-2-yl)-1H-indazole
  参考文献：
  名称：

  Indazole benzimidazole compounds

  摘要：

  本发明提供了结构为I的有机化合物，其中变量具有所述的值。药物制剂和药物包括该有机化合物或其药学上可接受的盐以及药学上可接受的载体，并可通过将该有机化合物或其药学上可接受的盐与载体和水混合来制备。治疗患者的方法包括向需要该药物制剂或药物的患者施用本发明的药物制剂或药物。

  公开号：

  US20030207883A1

文献信息

• 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF
  申请人：Samumed, LLC

  公开号：US20140194441A1

  公开（公告）日：2014-07-10

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地，本公开涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经系统疾病/疾患/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
  申请人：Samumed, LLC

  公开号：US10183929B2

  公开（公告）日：2019-01-22

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明公开了用于治疗各种疾病和病理的吲唑化合物。更具体地说，本公开涉及吲唑化合物或其类似物在治疗以 Wnt 通路信号激活为特征的疾病（如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病和骨关节炎）中的用途，以及吲唑化合物或其类似物的调节作用、癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病和骨关节炎）、Wnt 通路信号介导的细胞事件的调节，以及由于 Wnt 通路和/或一种或多种 Wnt 信号元件的突变或失调引起的遗传性疾病和神经系统状况/失调/疾病。此外，还提供了治疗 Wnt 相关疾病状态的方法。
• 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
  申请人：Samumed, LLC

  公开号：US10654832B2

  公开（公告）日：2020-05-19

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明公开了用于治疗各种疾病和病理的吲唑化合物。更具体地说，本公开涉及吲唑化合物或其类似物在治疗以 Wnt 通路信号激活为特征的疾病（如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病和骨关节炎）中的用途，以及吲唑化合物或其类似物的调节作用、癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病和骨关节炎）、Wnt 通路信号介导的细胞事件的调节，以及由于 Wnt 通路和/或一种或多种 Wnt 信号元件的突变或失调引起的遗传性疾病和神经系统状况/失调/疾病。此外，还提供了治疗 Wnt 相关疾病状态的方法。
• INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS
  申请人：CHIRON CORPORATION

  公开号：EP1401831A1

  公开（公告）日：2004-03-31
• US7064215B2
  申请人：——

  公开号：US7064215B2

  公开（公告）日：2006-06-20